About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Sept. 20 — National Medical Products Administration deputy director Yang Sheng said at a State Council Information Office briefing that during the 15th Five‑Year Plan period the NMPA will issue opinions to strengthen the drug safety responsibility fr

2026-09-20

Sept. 20 — National Medical Products Administration deputy director Yang Sheng said at a State Council Information Office briefing that during the 15th Five‑Year Plan period the NMPA will issue opinions to strengthen the drug safety responsibility framework, advance revisions to the Medical Device Administration Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, and fully implement the Drug Administration Law implementing rules and supporting systems. The agency will roll out a drug and medical‑device standards upgrade plan, compile a 2030 edition of the Chinese Pharmacopoeia prioritizing essential medicines, drugs covered by medical insurance and high-risk formulations, and step up standards research in frontier areas such as brain‑computer interfaces to drive quality improvements.

Other News
2026-09-20

William Lawrence, a professor of international relations at American University and a former senior U.S. diplomat, stated that although reports indicate Trump rejected Saudi Arabia's request to attack the Houthis, the U.S. may still intervene in the

William Lawrence, a professor of international relations at American University and a former senior U.S. diplomat, stated that although reports indicate Trump rejected Saudi Arabia's request to attack the Houthis, the U.S. may still intervene in the conflict. The U.S. will likely become more militarily involved in the confrontation between Saudi Arabia and the Houthis at some point. They have previously demonstrated their willingness to intervene when the Yemen issue affects their own interests. The conflicts in the Strait of Hormuz and the Bab el-Mandeb Strait are linked to the global economy and the U.S.'s security commitment to Saudi Arabia. In recent days, a growing number of Americans believe that the U.S. "needs to do something" to help protect Saudi Arabia and prevent the Houthis from consolidating their gains. The specific form of this intervention is unclear, but the U.S. is already deeply involved, with approximately 100 U.S. military advisors in Saudi Arabia providing extensive intelligence, surveillance, and reconnaissance support. Therefore, further U.S. involvement would not require a significant escalation.
2026-09-20

Sept. 20 — China’s National Medical Products Administration deputy director Yang Sheng told a State Council press briefing the agency will implement drug trial data protection and establish market exclusivity periods for pediatric medicines and rare-

Sept. 20 — China’s National Medical Products Administration deputy director Yang Sheng told a State Council press briefing the agency will implement drug trial data protection and establish market exclusivity periods for pediatric medicines and rare-disease treatments to better safeguard firms’ R&D investment. The NMPA will improve early-stage R&D communication, providing stronger pre-submission guidance for drugs with new targets or novel mechanisms. It will also expand a Spring Rain initiative to accelerate clinical translation of medical-device innovation and issue clinical trial and review guidance for frontier areas such as brain–computer interfaces to lay groundwork for future industry development.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.